Biotech - Spark Newswire

1 minute read

Autolus Therapeutics’ CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort

Today, 11:04 AM

Autolus Therapeutics plc (NASDAQ:AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell…

AUTL

1 minute read

EU Authorities Are Aware That A Batch Of The Active Substance For Janssen COVID-19 Vaccine Had Been Contaminated With Materials For Another Vaccine Manufactured At The Same Site.

By Bill Haddad

Today, 11:04 AM

-Reuters

JNJ

1 minute read

Constellation Pharmaceuticals Highlights Presentation Of Three Posters Relating To MANIFEST Trial Of Pelabresib At European Hematology Association Annual Meeting

By Bill Haddad

Today, 11:04 AM

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to

CNST

1 minute read

Atossa Therapeutics Receives Approval From Swedish Regulators To Initiate Phase 2 Clinical Study Of Oral Endoxifen To Reduce Mammographic Breast Density

By Bill Haddad

Today, 11:04 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and

ATOS

1 minute read

CHMP Approved New Manufacturing Site For Production Of Moderna COVID-19 Vaccine Finished Product, Site, Operated By Recipharm, Located In Monts; Changes Expected To Allow Production Of Additional 1M-2M Vials Of Ready-To-Use Vaccine For EU Mkt. Every Mo…

By Bill Haddad

Today, 11:04 AM

-Reuters

MRNA

4 minute read

The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts

By Shanthi Rexaline

Today, 11:04 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10)

ALKS

6 minute read

Keros Therapeutics Highlights Presentation Of Preclinical Data From ALK2 And KER-050 Hematology Programs At European Hematology Association EHA2021 Virtual Congress

By Bill Haddad

Today, 11:04 AM

Multiple poster presentations demonstrate that ALK2 inhibition lowered hepcidin levels and improved iron homeostasis in preclinical models of anemia and iron overload. Poster presentation demonstrates that

KROS

1 minute read

Aptose Presents For Corporate Update Event

By Bill Haddad

Today, 11:04 AM

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is

APTO

1 minute read

Incyte Announces FDA Has Extended New Drug Application Review Period For Ruxolitinib Cream For Treatment Of Atopic Dermatitis To Sept. 21 To Allow Time To Review Additional Analyses Submitted In Response To FDA’s Information Request

By Bill Haddad

Today, 11:04 AM

Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic

INCY